SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

Their core work

Syreon is a Budapest-based health economics and outcomes research (HEOR) consultancy specializing in health technology assessment, cost-effectiveness modelling, and evidence synthesis. They provide economic evaluations of healthcare interventions — from vaccination programmes to cancer screening and personalised medicine — helping policymakers and health systems make evidence-based funding decisions. Their work bridges the gap between clinical evidence and real-world health policy by developing payment models, multi-criteria decision frameworks, and outcome measurement tools for complex healthcare challenges.

What they specialise in

How they've shifted over time

In their earlier projects (2015–2018), Syreon focused on integrated care delivery models — how to organise, finance, and monitor health services for patients with multiple chronic conditions (SELFIE, EU-TOPIA, COMED). From 2019 onward, their work shifted decisively toward HTA methodology, real-world evidence, and the economics of specific interventions like vaccination and personalised medicine (HTx, VITAL, HEcoPerMed). The most recent project, EU-TOPIA-EAST (2021), signals growing interest in health equity and extending proven screening methods to underserved Eastern European populations.

Syreon is moving toward next-generation HTA methods that integrate real-world data and personalised treatment economics, positioning them at the centre of Europe's evolving health technology evaluation landscape.

How they like to work

Syreon operates exclusively as a consortium partner, never leading projects — a pattern consistent with a specialist research SME that brings targeted analytical capabilities rather than project management infrastructure. With 65 unique partners across 22 countries in just 7 projects, they join large, diverse consortia and rarely repeat the same partner group. This makes them an accessible and experienced collaborator: they know how to integrate into multinational teams and deliver their specific analytical contribution reliably.

Syreon has built a remarkably broad network for its size — 65 unique partners across 22 countries from just 7 projects, indicating participation in large consortia with major European health research institutions and HTA bodies. Their geographic reach spans all of Europe, including deliberate expansion into Eastern European health systems through EU-TOPIA-EAST.

What sets them apart

Syreon occupies a distinctive niche as a Central European health economics SME — small and agile enough to serve as a specialist partner, yet deeply embedded in the EU's HTA infrastructure through projects like HTx and alignment with EUnetHTA. Their combination of economic modelling, multi-criteria decision analysis, and real-world evidence expertise makes them a natural fit for any consortium that needs to demonstrate the cost-effectiveness or policy impact of a health intervention. Being based in Hungary also gives them credibility and local knowledge for projects targeting Eastern European health systems, a growing priority in EU health policy.

Highlights from their portfolio

• HTx
  Their largest funded project (EUR 679K) and most strategically important — defines next-generation HTA methodology using real-world data and EUnetHTA alignment.
• SELFIE
  Their first major H2020 project, establishing Syreon's reputation in multi-criteria decision analysis and integrated care model evaluation across Europe.
• EU-TOPIA-EAST
  Most recent project, extending cancer screening equity to Eastern Europe — signals Syreon's growing role as a bridge between Western and Eastern European health systems.